Category Archives: Pharmaceuticals and Healthcare

B-Cell Non-Hodgkin Lymphoma Therapeutics under Development by Companies


B-Cell Non-Hodgkin Lymphoma-Pipeline Insights, 2016, report provides in depth insights on the pipeline drugs and their development activities around the B-Cell Non-Hodgkin Lymphoma. The DelveInsightsReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsights Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for B-Cell Non-Hodgkin Lymphoma. DelveInsights Report also assesses the B-Cell Non-Hodgkin Lymphoma therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Request for Sample Market Report @


The report provides competitivepipeline landscape of B-Cell Non-Hodgkin Lymphoma
The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
Coverage of the B-Cell Non-Hodgkin Lymphoma pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
The report reviews key players involved in the therapeutics development for B-Cell Non-Hodgkin Lymphoma and also provide company profiling
The report also gives the information of dormant and discontinued pipeline projects
Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages

Reasons to buy Market Report

Complete Pipeline intelligence and complete understanding over therapeutics development for B-Cell Non-Hodgkin Lymphoma
Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
Devise corrective measures for pipeline projects by understanding B-Cell Non-Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics
Developing strategic initiatives to support your drug development activities.
Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Related Market Research Reports

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Global Clinical Trials Review, H2, 2016

Diffuse Large B-Cell Lymphoma – Pipeline Review, H2 2015

B-Cell Non-Hodgkin Lymphoma-Pipeline Insights, 2015

About Aarkstore:

Aarkstore Enterprise is among global marketing research companies involved in selling market reports across different industries and countries. We help serve thousands of clients annually with syndicated, custom market research and consulting. Collaborating with renowned market research partners, we have continued to etch our presence as an established as channel sales partner of market research intelligence on various frontiers. Clients from all sectors, including public, private, and commercial are endowed with best data modelling and processing structures with custom reports.

For further details, please Contact Us

Gain a high level view of the trends shaping and driving NSCLC market


Non-Small Cell Lung Cancer (NSCLC) – Current and Future Players, The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing NSCLC Market. The report identifies and analyses the key companies shaping and driving the global NSCLC market. The report provides insight into the competitive NSCLC landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GDs team of industry experts.

Request for Sample Report@


– Investigation of current and future market competition for NSCLC
– Competitor assessment
– Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
– Strategic assessment of NSCLC sector through market impact analysis, future market scenario and company analysis

Reasons to buy Market Report

– Gain a high level view of the trends shaping and driving NSCLC market
– Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
– Create an effective counter-strategy to gain a competitive advantage against those currently in the market
– Whats the next big thing in the global NSCLC market landscape? Identify, understand and capitalize

Related Market Research Reports

Non-Small Cell Lung Cancer (NSCLC) – China Drug Forecast and Market Analysis to 2025

Global Non-Small Cell Lung Cancer Partnering 2010 to 2017

Non-Small Cell Lung Cancer (NSCLC) – Japan Drug Forecast and Market Analysis to 2025

Human Papillomavirus Vaccine – Oncology drug report: 2006-2016 analysis, 2017-2021 expectations


“Gardasil: star cancer vaccine” is a comprehensive drug report on the market leader of HPV vaccine segment (according to 2015 sales).

In this report, Gardasil and Gardasil 9 are considered as a single product as Merck & Company reports the sales of both the vaccines collectively. Gardasil is the largest oncology vaccine and the largest in Merck’s oncology product portfolio. It is classified under the vaccine therapy and belongs to the HPV vaccine class. It is indicated for the prevention of cervical, vulvar, vaginal, and anal cancers. It is also approved for non-oncology indications and is known as ‘Silgard’ in Europe.

The report gives basic information about the vaccine, covering all details from brand name, date of approvals, mechanism of action, route of administration, etc. It has an interesting infographic description of the approval timeline and contains an event tracker, which covers all the major events surrounding the vaccine, news about Gardasil, information on competitor vaccine, number of clinical trials (by year and by phase), and so on.

Request for Sample Report@

Details of the sales analysis section

Historical annual sales analysis: Historical annual sales have been analysed with the help of graphical representation of sales over 2006 to Q3-2016. The report has all the data in tabular format as well. We have highlighted key reasons for the sales trend in all the geographies listed.

Historical quarterly sales analysis: Additionally, we have shown sales analysis on quarterly basis for the past 19 quarters from Q1-2012 to Q3-2016. The quarterly data is also in graphical as well as tabular format.

Expected sales analysis: The report has our expectations for Gardasil sales over 2016-2021. We have highlighted the key reasons for our expectations. All the historical as well as expected sales analysis is based on:

1.       Total global sales
2.       US sales
3.       International sales (Merck sales)

Other important details

Key event tracker: The report highlights key events that have taken place for Gardasil from 2006 to 2016 (along with those events expected in 2016). It gives additional information about the key events that have driven sales for the vaccine over this period.
Clinical trial numbers: The report provides numbers of clinical trials which have started for Gardasil in 2014, 2015 and 2016 and for different phases: phase II, phase II/III and phase III. It gives insights into whether the company is still spending money for taking the vaccine even further for other indications.
Competitive vaccines: Additionally, the vaccine which compete with Gardasil for the prevention of HPV disease listed with the details including brand name, API, company involved and first approval dates. It also provides comparison between the currently prevailing HPV vaccines.

Best Selling Healthcare Market Reports :

About Aarkstore:

Aarkstore Enterprise is a leading provider of business and financial information and solutions worldwide. We specialize in providing online market business information on market research reports, books, magazines, conference at competitive prices, and strive to provide excellent and innovative service to our customers.

Myocardial Fibrosis – Pipeline Review-2016


Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Fibrosis Pipeline Review, H2 2016, provides an overview of the Myocardial Fibrosis (Cardiovascular) pipeline landscape.

Myocardial fibrosis is an abnormal thickening of the heart valves due to inappropriate proliferation of cardiac fibroblasts. Symptoms include chest pain, some abdominal swelling, nausea and fatigue.


– The pipeline guide provides a snapshot of the global therapeutic landscape of Myocardial Fibrosis (Cardiovascular).
– The pipeline guide reviews pipeline therapeutics for Myocardial Fibrosis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Myocardial Fibrosis (Cardiovascular) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Myocardial Fibrosis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

Request for Sample Report@

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Myocardial Fibrosis Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Myocardial Fibrosis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myocardial Fibrosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocardial Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 1, 8 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Reasons to buy Market Report

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Myocardial Fibrosis (Cardiovascular).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Myocardial Fibrosis (Cardiovascular) pipeline depth and focus of Indication therapeutics.

Best Selling Market Reports : 

Cystic fibrosis – Epidemiology Forecast To 2023

Kidney Fibrosis – Pipeline Review, H2 2016

Pulmonary Fibrosis – Pipeline Review, H2 2016

About Aarkstore:

Aarkstore Enterprise is a leading provider of business and financial information and solutions worldwide. We specialize in providing online market business information on market research reports, books, magazines, conference at competitive prices, and strive to provide excellent and innovative service to our customers.

Seasonal Influenza Vaccine Market is expected to reach more than US$ 4 Billion By 2022

seasonal-influenza-vaccineSeasonal Influenza Vaccine Market is expected to reach more than US$ 4 Billion across the seven major markets (7MM) of the United States, France, Germany, Italy, Spain, United Kingdom and Japan by the year end of 2022.



Request for Sample Report @

Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against seasonal influenza, introduction of quadrivalent influenza vaccines, increase in the size of the elderly population in most countries. The barriers limiting the growth of the influenza market include limited patient awareness regarding the threat of influenza and the importance of influenza vaccinations, high investment and strict regulations act as barriers for new entrants.


The United States seasonal influenza vaccine market is the most attractive of those covered in the report. The United States market for seasonal influenza vaccine is expected to grow at a CAGR of XX% and is expected to reach at US$ XXX Million by the end of the forecasted period. United Kingdom will be the second–largest market for seasonal influenza vaccine which is expected to grow at a CAGR of XX% by 2022. Germany is expected to be third largest seasonal influenza vaccine market being followed by Japan by the end of the forecasted period.


Further, prudent analysis has been done on the competitor’s part, where three major players grab major share of the seasonal influenza vaccine market by revenue. Sanofi Pasteur, GlaxoSmithKline(GSK), Seqirus, AstraZeneca and Protein Sciences Corporation are the key influencers with their products in the seasonal influenza vaccine market. Other emerging players such as Novavax, Daiichi–Sankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd, and VaxInnate are making novel technology based influenza vaccine which is likely to affect the market share during the forecast period.


Seven Major Markets(7MM) covered in the report are as follows:

1. United States
2. United Kingdom
3. France
4. Italy
5. Spain
6. Germany
7. Japan

Major and Promising Vaccines covered in the report are as follows:

1. Fluzone High–Dose
2. Fluzone Quadrivalent
3. Intradermal (ID) Trivalent
4. Vaxigrip
5. Fluarix Quadrivalent
6. Flulaval Quadrivalent
7. Fluenz Tetra
8. FluMist Quadrivalent
9. Flublok
10. VN–100
11. M–001
12. VAX–2012Q
13. TAK – 850

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It also contains projection using a suitable set of assumptions and methodologies. It provides essential insights into seasonal influenza vaccine sales forecasts for the top seven countries, comprising the US, the UK, France, Italy, Spain, Germany and Japan until 2022. It also covers vaccination patterns and geographic distribution and offers a clear view of the regulatory landscape.

Best Selling Market Reports : 

Seasonal Allergic Rhinitis Global Clinical Trials Review, H2, 2016

Global Avian Influenza Vaccines Consumption 2016

United States Influenza Vaccine Industry 2016 Market Research Report

About Aarkstore:

Aarkstore Enterprise is a leading provider of business and financial information and solutions worldwide. We specialize in providing online market business information on market research reports, books, magazines, conference at competitive prices, and strive to provide excellent and innovative service to our customers.


Liver Cirrhosis- Market Insights, Epidemiology and Market Forecast-2023

Liver Cirrhosis


DelveInsights Liver Cirrhosis – Market Insights, Epidemiology and Market Forecast-2023 Reports provides an overview of the disease and global market trends of the Crohns disease for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Liver Cirrhosis forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Liver Cirrhosis till 2023.


Report covers the disease overview including etiology, path physiology, symptoms, diagnosis, disease management, and current treatment options.
Marketed information including available prescription drugs, its patent and exclusivity details followed by drug sales till 2018.
The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5, Japan and rest of the word from 2013-2023.
It also provides Liver Cirrhosis for United States, EU5 and Japan from 2013 and forecasted Market to 2023.

Browse The full Market Research Report @

Key Coverage and Benefits:

The report will help in developing business strategies by understanding the trends shaping and driving the global Liver Cirrhosis market.
Identifying patient populations in the global Liver Cirrhosismarket to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the best opportunities for Liver Cirrhosis therapeutics in each of the markets covered.
To understand the future market competition in the global Liver Cirrhosis therapeutics market and Insightful review of the key market drivers and barriers.

Best Selling Market Reports :

Europe Cod Liver Oil Market Report 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline Review, H2 2016

Traumatic Brain Injury- Market Insights, Epidemiology and Market Forecast-2023


Mayo Clinic – Strategic SWOT Analysis Review

Mayo Clinic


Mayo Clinic – Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.


– Business description A detailed description of the companys operations and business divisions.
– Corporate strategy GlobalDatas summarization of the companys business strategy.
– SWOT analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
– Company history Progression of key events associated with the company.
– Major products and services A list of major products, services and brands of the company.
– Key competitors A list of key competitors to the company.
– Key employees A list of the key executives of the company.
– Executive biographies A brief summary of the executives employment history.
– Key operational heads A list of personnel heading key departments/functions.
– Important locations and subsidiaries A list of key locations and subsidiaries of the company, including contact details.
– Key manufacturing facilities A list of key manufacturing facilities of the company.

Browse full report @


Mayo Clinic (Mayo) formerly known as Mayo Clinic Jacksonville is a not-for-profit healthcare organization. The organization provides comprehensive medical facilities and programs related to healthcare education, and research and patient care services. It provides treatments for diseases such as cancer, bipolar disorder, brachial plexus injury, tumors, burning mouth syndrome, eating disorders, epilepsy, infectious diseases, lung diseases, melanoma, Alzheimers and Parkinsons disease, temporomandibular joint (TMJ) disorders, womens health, Wilsons disease and Wolff-Parkinson-White (WPW) syndrome, among others. Mayo operates through its various medical departments that include aerospace medicine, allergy, breast cancer, emergency medicine, medical genetics, pathology, radiology, oncology, neurology, nephrology, ophthalmology and others. Mayo Clinic is headquartered in Jacksonville, Florida, the US.

Reasons to Buy

– Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
– Identify potential customers and suppliers with this reports analysis of the companys business structure, operations, major products and services and business strategy.
– Understand and respond to your competitors business structure and strategies with GlobalDatas detailed SWOT analysis. In this, the companys core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
– Examine potential investment and acquisition targets with this reports detailed insight into the companys strategic, business and operational performance.

Best Selling Reports :

Mayo Clinic US – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Singapore Telecommunications Limited (Z74) – Financial and Strategic SWOT Analysis Review

Mind C.T.I. Ltd. (MNDO) – Financial and Strategic SWOT Analysis Review


%d bloggers like this: